We are live on ! Find out more
AEON icon

AEON Biopharma
AEON

21 hedge funds and large institutions have $20.5M invested in AEON Biopharma in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 13 reducing their positions, and 69 closing their positions.

New
Increased
Maintained
Reduced
Closed

1.15% less ownership

Funds ownership: 1.24% → 0.1% (-1.1%)

75% less funds holding

Funds holding: 85 → 21 (-64)

85% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 13

92% less capital invested

Capital invested by funds: $248M → $20.5M (-$228M)

93% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 69

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
21
Holders Change
-64
Holders Change %
-75.29%
% of All Funds
0.33%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
5
Increased
2
Reduced
13
Closed
69
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SIM
Sandia Investment Management
Massachusetts
+$1.31M
2
Deutsche Bank
Deutsche Bank
Germany
+$546K
3
Walleye Capital
Walleye Capital
New York
+$161K
4
CCM
CAAS Capital Management
New York
+$119K
5
FTUS
Flow Traders U.S.
New York
+$107K

Top Sellers

Rank Fund Capital Flow
1
Marshall Wace
Marshall Wace
United Kingdom
-$13.3M
2
DKCM
Davidson Kempner Capital Management
New York
-$12.8M
3
AC
Aristeia Capital
Connecticut
-$12.6M
4
ECP
Empyrean Capital Partners
California
-$12.1M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$11.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
HSBC Holdings
26
HSBC Holdings
United Kingdom
– -$10.1M -13,948 Closed
RCM
27
Radcliffe Capital Management
Pennsylvania
– -$8.98M -12,404 Closed
LP
28
LMR Partners
United Kingdom
– -$6.03M -8,333 Closed
Bank of Montreal
29
Bank of Montreal
Ontario, Canada
– -$5.86M -8,100 Closed
CIM
30
Cowen Investment Management
New York
– -$5.78M -7,986 Closed
WCMNY
31
Westchester Capital Management (New York)
New York
– -$5.56M -7,673 Closed
KIM
32
Karpus Investment Management
New York
– -$5.53M -7,594 Closed
AMC
33
Atlas Merchant Capital
New York
– -$5.45M -7,528 Closed
Hudson Bay Capital Management
34
Hudson Bay Capital Management
Connecticut
– -$5.44M -7,511 Closed
CH
35
CVI Holdings
Delaware
– -$5.05M -6,979 Closed
SC
36
Sculptor Capital
New York
– -$4.82M -6,656 Closed
AA
37
AQR Arbitrage
Connecticut
– -$4.13M -5,704 Closed
MF
38
Magnetar Financial
Illinois
– -$4.06M -5,613 Closed
FTCM
39
First Trust Capital Management
Illinois
– -$3.79M -5,240 Closed
Millennium Management
40
Millennium Management
New York
– -$3.66M -5,056 Closed
DFCM
41
Dark Forest Capital Management
Puerto Rico
– -$3.65M -5,051 Closed
QL
42
Quarry LP
New York
– -$3.1M -4,289 Closed
WA
43
Whitebox Advisors
Minnesota
– -$3.03M -4,181 Closed
State of Wisconsin Investment Board
44
State of Wisconsin Investment Board
Wisconsin
– -$2.89M -3,985 Closed
Goldman Sachs
45
Goldman Sachs
New York
– -$2.79M -3,854 Closed
HIM
46
HGC Investment Management
Ontario, Canada
– -$2.51M -3,472 Closed
KL
47
KIM LLC
Kansas
– -$2.51M -3,472 Closed
ETH
48
Exos TFP Holdings
New York
– -$2.42M -3,339 Closed
MTCM
49
Mint Tower Capital Management
Netherlands
– -$2.35M -3,254 Closed
Nomura Holdings
50
Nomura Holdings
Japan
– -$2.26M -3,132 Closed
1
2
3 4

AEON Hedge Fund Activity: Q1 2023 in Review

21 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma (AEON) for Q1 2023, worth a combined $20.5M — down 92% from $248M a quarter earlier.

Sellers outnumbered buyers: 69 funds closed out of AEON and 5 opened new positions — a net loss of 64 holders — while 13 trimmed existing stakes and 2 added.

The largest buyer was Sandia Investment Management, opening a new position worth an estimated $1.31M. The largest seller was Marshall Wace, exiting entirely with an estimated $13.3M sold.

  • 21 institutional investors held AEON Biopharma (AEON) as of Q1 2023, down from 85 in Q4 2022.
  • Funds reported $20.5M of AEON Biopharma stock for Q1 2023, down 92% quarter-over-quarter.
  • 5 funds opened new AEON Biopharma positions in Q1 2023 and 69 closed out, a net change of -64 holders.
  • The largest AEON Biopharma buyer in Q1 2023 was Sandia Investment Management, an estimated $1.31M added.
  • The largest AEON Biopharma seller in Q1 2023 was Marshall Wace, an estimated $13.3M sold.

Based on aggregated 13F filings for Q1 2023.